0.50Open0.10Pre Close22 Volume64 Open Interest1.50Strike Price628.00Turnover131.02%IV20.30%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.4070Delta0.9614Gamma13.30Leverage Ratio-0.0041Theta0.0002Rho5.41Eff Leverage0.0012Vega
ATAI Life Sciences Stock Discussion
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
• ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hour...
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
atai Life Sciences has provided an update on Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a synthetic psilocin formulation designed for a consistent and shorter treatment duration of approximately two hours. The Phas...
Benzinga· 2 mins ago
Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley's novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.)
See: Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development
...
Benzinga· 2 mins ago
No comment yet